# A Study of LY3200882 in Participants With Solid Tumors

> **NCT02937272** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 223 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** LY3200882
- **DRUG:** LY3300054
- **DRUG:** Gemcitabine
- **DRUG:** nab-Paclitaxel
- **DRUG:** Cisplatin
- **RADIATION:** Intensity Modulated Radiotherapy

## Key facts

- **NCT ID:** NCT02937272
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-11-21
- **Primary completion:** 2020-02-27
- **Final completion:** 2027-08
- **Target enrollment:** 223 (ESTIMATED)
- **Last updated:** 2026-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02937272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02937272, "A Study of LY3200882 in Participants With Solid Tumors". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02937272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*